Zentalis Pharmaceuticals
ZNTL
107 hedge funds and large institutions have $1.94B invested in Zentalis Pharmaceuticals in 2020 Q4 according to their latest regulatory filings, with 47 funds opening new positions, 41 increasing their positions, 13 reducing their positions, and 5 closing their positions.
840% more first-time investments, than exits
New positions opened: 47 | Existing positions closed: 5
215% more repeat investments, than reductions
Existing positions increased: 41 | Existing positions reduced: 13
85% more capital invested
Capital invested by funds: $1.05B → $1.94B (+$889M)
62% more funds holding
Funds holding: 66 → 107 (+41)
11.65% more ownership
Funds ownership: 80.2% → 91.85% (+12%)
0% more funds holding in top 10
Funds holding in top 10: 1 → 1 (0)
Top Buyers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
Fidelity Investments
Boston,
Massachusetts
|
+$146M |
| 2 |
BlackRock
New York
|
+$59.3M |
| 3 |
Vanguard Group
Malvern,
Pennsylvania
|
+$54.7M |
| 4 |
State Street
Boston,
Massachusetts
|
+$32.9M |
| 5 |
APM
Avidity Partners Management
Dallas,
Texas
|
+$10.4M |
Top Sellers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
Viking Global Investors
Stamford,
Connecticut
|
-$64.6M |
| 2 |
FCM
Farallon Capital Management
San Francisco,
California
|
-$32.4M |
| 3 |
SAM
Sectoral Asset Management
Montreal,
Quebec, Canada
|
-$18.2M |
| 4 |
Citadel Advisors
Miami,
Florida
|
-$8.38M |
| 5 |
MC
Mayo Clinic
Rochester,
Minnesota
|
-$3.62M |
ZNTL Hedge Fund Activity: Q4 2020 in Review
107 of the 5,651 institutional investors tracked by Wall St. Rank reported a position in Zentalis Pharmaceuticals (ZNTL) for Q4 2020, worth a combined $1.94B — up 85% from $1.05B a quarter earlier.
Buyers outnumbered sellers: 47 funds opened new ZNTL positions and 5 closed out — a net gain of 42 holders — while 41 added to existing stakes and 13 trimmed.
The largest buyer was Fidelity Investments, adding an estimated $146M. The largest seller was Viking Global Investors, cutting an estimated $64.6M.
- 107 institutional investors held Zentalis Pharmaceuticals (ZNTL) as of Q4 2020, up from 66 in Q3 2020.
- Funds reported $1.94B of Zentalis Pharmaceuticals stock for Q4 2020, up 85% quarter-over-quarter.
- 47 funds opened new Zentalis Pharmaceuticals positions in Q4 2020 and 5 closed out, a net change of +42 holders.
- The largest Zentalis Pharmaceuticals buyer in Q4 2020 was Fidelity Investments, an estimated $146M added.
- The largest Zentalis Pharmaceuticals seller in Q4 2020 was Viking Global Investors, an estimated $64.6M sold.
Based on aggregated 13F filings for Q4 2020.